<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01776268</url>
  </required_header>
  <id_info>
    <org_study_id>121760</org_study_id>
    <nct_id>NCT01776268</nct_id>
  </id_info>
  <brief_title>Effect of Colostrum on Mucosal Immunity in Very Low Birth Weight (VLBWs) Premature Infants</brief_title>
  <official_title>Effect of Colostrum on Innate Mucosal Immunity in Very Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Infection in preterm infants is a common, costly, and devastating problem frequently causing
      death or sequelae for survivors. An immature immune system underlies the frequency and
      severity of infections in this vulnerable population. The mouth is the site where microbes
      first meet the mucosal immune system. Antimicrobial proteins and peptides (APPs) in saliva
      kill microbes and improve immune cell function. Low APP levels increase the risk of
      developing infection. Colostrum and human milk reduce the risk of infection. This protective
      effect of human milk may come from supplying or stimulating infant production of APPs. No
      prior investigation has determined the concentration of APPs in saliva or the effect of human
      milk/formula on the APP concentrations in saliva.

      Objective(s) and Hypothesis(es):

      The investigators objectives are to identify and serially determine the concentrations of key
      APPs in colostrum, human milk, and preterm infant saliva using highly-sensitive and specific
      mass spectroscopy methods. The investigators study is designed to test the hypotheses that
      (a) all saliva APPs increase over time, (b) APP concentrations are higher in colostrum as
      compared to human milk, and (c) APPs are increased in saliva of infants that receive
      colostrum orally compared to those that do not.

      Potential Impact:

      If increased saliva APP levels are associated with oral colostrum priming, this discovery
      would advance understanding of the immune properties of human milk and identify oral APPs as
      important immune elements and potential therapeutic targets in this vulnerable population.
      This knowledge has the potential to alter feeding practices and provide a safe, low cost
      means to improve immune function and significantly improve outcomes for preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Between 20 and 60% of very low birth weight (VLBW) infants are diagnosed with
      infection during their initial hospitalization2-9. Infection in preterm infants is a costly
      and devastating problem associated with high mortality and debilitating survivor morbidity.
      High infection rates are attributed to suboptimal preterm neonatal immune function. In depth
      investigation of the unique properties of the preterm neonatal immune function is necessary
      to identify novel interventions that can translate into improved neonatal outcomes.

      Mucosal surfaces are critical immune barriers that shield against host microbial invasion by
      surface-colonizing commensal or potentially pathogenic organisms. Antimicrobial proteins and
      peptides (APPs) on mucosal surfaces reduce microbial burden individually and synergistically
      by direct killing of microbes and by improving immune surveillance through activation of
      local sentinel cells. Deficiencies in these innate immune proteins predispose the host to
      infection or dysregulated inflammation. Two major classes of APPs (defensins and
      cathelicidin) are present on mucosal surfaces in adults. Colostrum and human milk (HM)
      contain some APPs that may play an adjuvant role on mucosal sites including the mouth. HM
      ingestion is associated with a decreased risk of developing sepsis and necrotizing
      enterocolitis in preterm infants. One potential mechanism behind the reduction in infection
      risk associated with HM feeding may be enhanced immunocompetence through provision of APPs
      and induction of neonatal APP production. Investigators are not aware of any investigation
      that has determined the neonatal salivary concentration of any APP or the effect of oral
      priming (OP) with colostrum on the concentration of salivary APPs. It is also unknown whether
      OP with formula modifies salivary APPs.

      Objectives and Hypotheses: Our objectives are to determine: 1) the concentration of salivary
      APPs from preterm infants at baseline and 7 days later, 2) the effect of oral priming (OP)
      with either human milk or formula on salivary APP concentrations, and 3) the concentration of
      APPs in colostrum as compared to milk. Our hypotheses are: 1) All salivary APPs increase over
      time in preterm infants (with or without OP) 2) Compared with formula OP or no OP, colostrum
      OP is associated with a significantly greater increase in salivary LL-37 and hBD2
      concentrations and 3) Colostrum contains a greater concentration of LL-37 compared to human
      milk.

      Design: Following the mother's decision to provide human milk or formula to her preterm
      newborn, VLBW infants will be randomized to receive OP or not. Investigators will compare the
      concentration of salivary APPs from VLBW infants that receive OP to VLBW infants that do not.
      Saliva will be sampled prior to and after 5 days of OP. Time-matched saliva samples will be
      obtained from the infants that do not receive OP. APP concentrations will be compared between
      the biological mother's colostrum (both whey and fat fractions) and her transitional milk
      (produced &gt;7 days after birth). To account for the heterogeneous VLBW population,
      investigators will study 200 infants (50 infants/group, 4 groups) to test our hypotheses.
      Both inborn and outborn VLBW infants are eligible. Exclusion criteria include infants with a
      medical contraindication for oral or enteral feeds, congenital anomalies or chromosomal
      disorders. Saliva and milk-based proteomes including APPs will be determined using Matrix
      Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF).

      Potential Impact: This is the first study of APPs in saliva of human neonates. If increased
      saliva APP levels are associated with colostrum OP, this discovery would add to our
      understanding of the immune properties of human milk. Identification of APPs as important
      elements that improve immune function is likely to alter the approach to infant nutrition and
      improve outcomes for premature infants. Ultimately, our goal is to determine whether there is
      an association between APP levels in neonatal saliva and the incidence of neonatal infection
      (including NEC) in an appropriately powered clinical study based on the data generated in
      this proposal.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of APPs Before Oral Priming</measure>
    <time_frame>days 1-2 of life</time_frame>
    <description>Saliva will be sampled on day 1-2 of life prior to oral priming. Investigators are assessing saliva for a change in the concentration of antimicrobial proteins.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of APPs After Oral Priming</measure>
    <time_frame>days 7-9 of life</time_frame>
    <description>Saliva will be sampled 24-48 hours after the 5-days of oral priming is completed. Investigators are assessing saliva for a change in the concentration of antimicrobial proteins.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Prematurity</condition>
  <arm_group>
    <arm_group_label>Oral priming</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No oral priming</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No oral priming</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral priming</intervention_name>
    <description>Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.</description>
    <arm_group_label>Oral priming</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Very low birth weight (&lt;1500 g)

          -  Gestational age &lt;30 weeks

          -  Admission to NICU (born at Vanderbilt or transferred in for care)

          -  English or Spanish-speaking parents

        Exclusion Criteria:

          -  Does not meet inclusion criteria

          -  Parent does not give study consent

          -  Has congenital anomalies, chromosomal disorder or medical contraindication to
             oral/enteral feedings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Wynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monroe Carell Jr Children's Hospital at Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0656</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nature.com/jp/journal/v37/n1/full/jp2016161a.html</url>
    <description>Oral colostrum priming shortens hospitalization without changing the immunomicrobial milieu</description>
  </link>
  <reference>
    <citation>Romano-Keeler J, Azcarate-Peril MA, Weitkamp JH, Slaughter JC, McDonald WH, Meng S, Latuga MS, Wynn JL. Oral colostrum priming shortens hospitalization without changing the immunomicrobial milieu. J Perinatol. 2017 Jan;37(1):36-41. doi: 10.1038/jp.2016.161. Epub 2016 Sep 29.</citation>
    <PMID>27684425</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>June 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2017</results_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>James Wynn</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>antimicrobial proteins</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Colostrum Priming</title>
          <description>Intervention:Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.</description>
        </group>
        <group group_id="P2">
          <title>no Oral Priming</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Priming</title>
          <description>Intervention:Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.</description>
        </group>
        <group group_id="B2">
          <title>no Oral Priming</title>
          <description>No oral priming: no intervention</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Gestational age in weeks</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="27" upper_limit="31"/>
                    <measurement group_id="B2" value="29" lower_limit="28" upper_limit="30"/>
                    <measurement group_id="B3" value="29" lower_limit="27" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Mother's Ethnicity is reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Mother's Race is reported</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Weight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1272" lower_limit="988" upper_limit="1602"/>
                    <measurement group_id="B2" value="1170" lower_limit="905" upper_limit="1340"/>
                    <measurement group_id="B3" value="1219" lower_limit="905" upper_limit="1602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>APGAR</title>
          <description>APGAR 0=worst 10=best Activity, Pulse, Grimace, Appearance, and Respiration.
Activity 0 Limp
Some flexion of arms and legs
Active motion
Pulse 0 No heart rate
&lt;100 beats per minute
At least 100 beats/minute
Grimace during suctioning 0 No response
Grimace
Grimace and pull away, cough
Appearance 0 whole body bluish-gray or pale
Good color in body with bluish hands or feet
Good color all over
Respiration 0 Not breathing
Weak cry; , slow or irregular breathing
Good, strong cry; normal rate and effort of breathing</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="B2" value="7" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="B3" value="7" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of APPs Before Oral Priming</title>
        <description>Saliva will be sampled on day 1-2 of life prior to oral priming. Investigators are assessing saliva for a change in the concentration of antimicrobial proteins.</description>
        <time_frame>days 1-2 of life</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Priming</title>
            <description>Intervention:Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.</description>
          </group>
          <group group_id="O2">
            <title>No Oral Priming</title>
          </group>
        </group_list>
        <measure>
          <title>Concentration of APPs Before Oral Priming</title>
          <description>Saliva will be sampled on day 1-2 of life prior to oral priming. Investigators are assessing saliva for a change in the concentration of antimicrobial proteins.</description>
          <units>femtomole (fmol)</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S100a7-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="8" upper_limit="39"/>
                    <measurement group_id="O2" value="22" lower_limit="7" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a7-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="5" upper_limit="60"/>
                    <measurement group_id="O2" value="42" lower_limit="5" upper_limit="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a8-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="39" upper_limit="313"/>
                    <measurement group_id="O2" value="102" lower_limit="49" upper_limit="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a8-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495" lower_limit="190" upper_limit="854"/>
                    <measurement group_id="O2" value="683" lower_limit="109" upper_limit="1064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a9-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1669" lower_limit="755" upper_limit="2540"/>
                    <measurement group_id="O2" value="2392" lower_limit="287" upper_limit="3465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a9-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" lower_limit="112" upper_limit="337"/>
                    <measurement group_id="O2" value="364" lower_limit="67" upper_limit="614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surfactant protein A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>α-Defensin 1-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>α-Defensin 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactoferrin-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="1" upper_limit="23"/>
                    <measurement group_id="O2" value="15" lower_limit="1" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactoferrin-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7" upper_limit="17"/>
                    <measurement group_id="O2" value="14" lower_limit="8" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="196"/>
                    <measurement group_id="O2" value="10" lower_limit="10" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lysozyme C-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1257" lower_limit="698" upper_limit="2184"/>
                    <measurement group_id="O2" value="1122" lower_limit="559" upper_limit="2058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lysozyme C-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of APPs After Oral Priming</title>
        <description>Saliva will be sampled 24-48 hours after the 5-days of oral priming is completed. Investigators are assessing saliva for a change in the concentration of antimicrobial proteins.</description>
        <time_frame>days 7-9 of life</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Priming</title>
            <description>Intervention:Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.</description>
          </group>
          <group group_id="O2">
            <title>No Oral Priming</title>
            <description>No oral priming</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of APPs After Oral Priming</title>
          <description>Saliva will be sampled 24-48 hours after the 5-days of oral priming is completed. Investigators are assessing saliva for a change in the concentration of antimicrobial proteins.</description>
          <units>femtomole (fmol)</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S100a7-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="8" upper_limit="27"/>
                    <measurement group_id="O2" value="20" lower_limit="9" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a7-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="5" upper_limit="68"/>
                    <measurement group_id="O2" value="38" lower_limit="5" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a8-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="44" upper_limit="308"/>
                    <measurement group_id="O2" value="206" lower_limit="57" upper_limit="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a8-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="511" lower_limit="197" upper_limit="789"/>
                    <measurement group_id="O2" value="562" lower_limit="252" upper_limit="1037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a9-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1777" lower_limit="934" upper_limit="2473"/>
                    <measurement group_id="O2" value="1886" lower_limit="731" upper_limit="4008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S100a9-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241" lower_limit="114" upper_limit="311"/>
                    <measurement group_id="O2" value="319" lower_limit="114" upper_limit="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surfactant protein A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>α-Defensin 1-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>α-Defensin 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactoferrin-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="1" upper_limit="92"/>
                    <measurement group_id="O2" value="29" lower_limit="1" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactoferrin-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="14" upper_limit="103"/>
                    <measurement group_id="O2" value="21" lower_limit="12" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunoglobulin A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="29" upper_limit="1373"/>
                    <measurement group_id="O2" value="42" lower_limit="10" upper_limit="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lysozyme C-S1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1680" lower_limit="836" upper_limit="3416"/>
                    <measurement group_id="O2" value="1972" lower_limit="1344" upper_limit="2617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lysozyme C-S2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="0" upper_limit="31"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Priming</title>
          <description>Intervention:Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.</description>
        </group>
        <group group_id="E2">
          <title>no Oral Priming</title>
          <description>No oral priming: no intervention</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Wynn MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <email>james.wynn@peds.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

